Advertisement

Search Results

Advertisement



Your search for Franck Morschhauser, MD, PhD,Franck Morschhauser, MD, PhD matches 6 pages

Showing 1 - 6


lymphoma

First-Line Lenalidomide/Rituximab vs Rituximab/Chemotherapy With Rituximab Maintenance for Advanced Follicular Lymphoma

As reported in the Journal of Clinical Oncology by Franck Morschhauser, MD, PhD, and colleagues, 6-year results from the second interim analysis of the phase III RELEVANCE trial show similar progression-free and overall survival with lenalidomide/rituximab (R2) vs rituximab/chemotherapy (R-chemo)...

hematologic malignancies
lymphoma

Combination Immunotherapy With Lenalidomide Plus Rituximab in Indolent NHL: Time to Replace Rituximab Monotherapy?

With increasing knowledge on the key role of the tumor microenvironment in lymphomagenesis, treatments for indolent B-cell lymphoma, especially follicular lymphoma, are mechanistically moving toward a more immunomodulatory approach. Chemotherapy-free regimens are an attractive alternative to...

hematologic malignancies
lymphoma

Rituximab/Lenalidomide vs Rituximab/Chemotherapy in Advanced Untreated Follicular Lymphoma

In the phase III RELEVANCE trial reported in The New England Journal of Medicine by Franck Morschhauser, MD, PhD, of The University of Lille, Centre Hospitalier Universitaire Lille, France, and colleagues, no difference in the complete response rate or interim progression-free survival was found...

lymphoma

ICML 2017: Phase II Trial of Tazemetostat in Relapsed or Refractory Follicular Lymphoma and DLBCL

Positive interim efficacy data from an ongoing phase II clinical trial of tazemetostat, a first-in-class, oral enhancer of zeste homolog 2 (EZH2) inhibitor, as a single-agent treatment for relapsed or refractory patients with follicular lymphoma or diffuse large B-cell lymphoma (DLBCL) grouped by...

lymphoma

Obinutuzumab Shows Activity in Relapsed/Refractory Diffuse Large B-cell Lymphoma or Mantle Cell Lymphoma and Indolent Non-Hodgkin Lymphoma 

Obinutuzumab is a type II, glycoengineered, humanized anti-CD20 monoclonal antibody. In the phase II GAUGUIN studies reported in the Journal of Clinical Oncology by Franck Andre Morschhauser, MD, PhD, of Centre Hospitalier Régional Universitaire de Lille and Gilles A. Salles, MD, PhD, of Hospices...

lymphoma

Obinutuzumab Shows Activity in Relapsed/Refractory Diffuse Large B-cell Lymphoma or Mantle Cell Lymphoma and Indolent Non-Hodgkin Lymphoma

Obinutuzumab is a type II, glycoengineered, humanized anti-CD20 monoclonal antibody. In the phase II GAUGUIN studies reported in Journal of Clinical Oncology by Franck Andre Morschhauser, MD, PhD of Centre Hospitalier Régional Universitaire de Lille and Gilles A. Salles, MD, PhD, of Hospices ...

Advertisement

Advertisement




Advertisement